Virus suppression, eradication, or tolerance to treatment in patients with chronic hepatitis B

摘要

In their Review, Robert Gish and colleagues1 provided an overview of the mechanisms of antiviral drug resistance of chronic hepatitis B and drew attention to the importance of selecting a first-line treatment, such as entecavir or tenofovir, with a high threshold for resistance. The Review will be very helpful for understanding and choosing the correct treatment. Although success rates for treatment of chronic hepatitis B have been improving during the recent decades, the confirmed treatment strategy seems to only focus on the permutation and combination of antiviral drugs. Moreover, most patients with chronic hepatitis B require long-term and even lifetime treatment.